Literature DB >> 27852697

Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal Masses.

Adriaan Vanderstichele1,2, Pieter Busschaert1,2, Dominiek Smeets3,4, Chiara Landolfo1, Els Van Nieuwenhuysen1,2, Karin Leunen1,2, Patrick Neven1,2, Frédéric Amant1,2,5, Sven Mahner6,7, Elena Ioana Braicu8, Robert Zeilinger9, An Coosemans1,2, Dirk Timmerman1, Diether Lambrechts10,4, Ignace Vergote1,2.   

Abstract

Purpose: Chromosomal instability is a hallmark of ovarian cancer. Here, we explore copy-number alteration (CNA) profiling in cell-free DNA as a potential biomarker to detect malignancy in patients presenting with an adnexal mass.Experimental Design: We prospectively enrolled 68 patients with an adnexal mass, of which 57 were diagnosed with invasive or borderline carcinoma and 11 with benign disease. Cell-free DNA was extracted from plasma and analyzed by low-coverage whole-genome sequencing.
Results: Patterns of chromosomal instability were detectable in cell-free DNA using 44 healthy individuals as a reference. Profiles were representative of those observed in matching tumor tissue and contained CNAs enriched in two large datasets of high-grade serous ovarian cancer (HGSOC). Quantitative measures of chromosomal instability, referred to as genome-wide z-scores, were significantly higher in patients with ovarian carcinoma than in healthy individuals or patients with benign disease. Cell-free DNA testing improved malignancy detection (AUC 0.89) over serum CA-125 (AUC 0.78) or the risk of malignancy index (RMI, AUC 0.81). AUC values of cell-free DNA testing even further increased for HGSOC patients specifically (AUC 0.94). At a specificity of 99.6%, a theoretical threshold required for ovarian cancer screening, sensitivity of cell-free DNA testing was 2- to 5-fold higher compared with CA-125 and RMI testing.Conclusions: This is the first study evaluating the potential of cell-free DNA for the diagnosis of primary ovarian cancer using chromosomal instability as a read-out. We present a promising method to increase specificity of presurgical prediction of malignancy in patients with adnexal masses. Clin Cancer Res; 23(9); 2223-31. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27852697     DOI: 10.1158/1078-0432.CCR-16-1078

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  28 in total

Review 1.  Liquid Biopsy in the Clinical Management of High-Grade Serous Epithelial Ovarian Cancer-Current Use and Future Opportunities.

Authors:  Lara Paracchini; Maurizio D'Incalci; Sergio Marchini
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

2.  LiquidCNA: Tracking subclonal evolution from longitudinal liquid biopsies using somatic copy number alterations.

Authors:  Eszter Lakatos; Helen Hockings; Maximilian Mossner; Weini Huang; Michelle Lockley; Trevor A Graham
Journal:  iScience       Date:  2021-07-21

3.  Whole-genome/exome analysis of circulating tumor DNA and comparison to tumor genomics from patients with heavily pre-treated ovarian cancer: subset analysis of the PERMED-01 trial.

Authors:  Renaud Sabatier; Séverine Garnier; Arnaud Guille; Nadine Carbuccia; Jihane Pakradouni; José Adelaide; Magali Provansal; Maria Cappiello; Frédérique Rousseau; Max Chaffanet; Daniel Birnbaum; Emilie Mamessier; Anthony Gonçalves; François Bertucci
Journal:  Front Oncol       Date:  2022-07-29       Impact factor: 5.738

Review 4.  Circulating tumor cells and cell-free nucleic acids in patients with gynecological malignancies.

Authors:  Ben Davidson
Journal:  Virchows Arch       Date:  2018-08-25       Impact factor: 4.064

Review 5.  Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells.

Authors:  Ugo Testa; Eleonora Petrucci; Luca Pasquini; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2018-02-01

Review 6.  Circulating cell-free DNA and circulating tumor cells, the "liquid biopsies" in ovarian cancer.

Authors:  Xianliang Cheng; Lei Zhang; Yajuan Chen; Chen Qing
Journal:  J Ovarian Res       Date:  2017-11-13       Impact factor: 4.234

Review 7.  Implementing liquid biopsies into clinical decision making for cancer immunotherapy.

Authors:  Dagmar Quandt; Hans Dieter Zucht; Arno Amann; Anne Wulf-Goldenberg; Carl Borrebaeck; Michael Cannarile; Diether Lambrechts; Herbert Oberacher; James Garrett; Tapan Nayak; Michael Kazinski; Charles Massie; Heidi Schwarzenbach; Michele Maio; Robert Prins; Björn Wendik; Richard Hockett; Daniel Enderle; Mikkel Noerholm; Hans Hendriks; Heinz Zwierzina; Barbara Seliger
Journal:  Oncotarget       Date:  2017-07-18

8.  Validation of the Performance of International Ovarian Tumor Analysis (IOTA) Methods in the Diagnosis of Early Stage Ovarian Cancer in a Non-Screening Population.

Authors:  Wouter Froyman; Laure Wynants; Chiara Landolfo; Tom Bourne; Lil Valentin; Antonia Testa; Povilas Sladkevicius; Dorella Franchi; Daniela Fischerova; Luca Savelli; Ben Van Calster; Dirk Timmerman
Journal:  Diagnostics (Basel)       Date:  2017-06-02

Review 9.  ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors.

Authors:  Dirk Timmerman; François Planchamp; Tom Bourne; Chiara Landolfo; Andreas du Bois; Luis Chiva; David Cibula; Nicole Concin; Daniela Fischerova; Wouter Froyman; Guillermo Gallardo Madueño; Birthe Lemley; Annika Loft; Liliana Mereu; Philippe Morice; Denis Querleu; Antonia Carla Testa; Ignace Vergote; Vincent Vandecaveye; Giovanni Scambia; Christina Fotopoulou
Journal:  Int J Gynecol Cancer       Date:  2021-06-10       Impact factor: 3.437

10.  High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification.

Authors:  Siel Olbrecht; Pieter Busschaert; Junbin Qian; Adriaan Vanderstichele; Liselore Loverix; Toon Van Gorp; Els Van Nieuwenhuysen; Sileny Han; Annick Van den Broeck; An Coosemans; Anne-Sophie Van Rompuy; Diether Lambrechts; Ignace Vergote
Journal:  Genome Med       Date:  2021-07-09       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.